NASDAQ:TTPH - Tetraphase Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.82 -0.02 (-2.38 %) (As of 05/22/2019 04:00 PM ET)Previous Close$0.84Today's Range$0.80 - $0.9352-Week Range$0.75 - $4.49Volume419,300 shsAverage Volume611,368 shsMarket Capitalization$44.50 millionP/E RatioN/ADividend YieldN/ABeta2.85 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts. Receive TTPH News and Ratings via Email Sign-up to receive the latest news and ratings for TTPH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TTPH Previous Symbol CUSIPN/A CIK1373707 Webhttp://www.tphase.com/ Phone617-715-3600Debt Debt-to-Equity Ratio0.53 Current Ratio7.28 Quick Ratio7.10Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$18.90 million Price / Sales2.35 Cash FlowN/A Price / Cash FlowN/A Book Value$1.16 per share Price / Book0.71Profitability EPS (Most Recent Fiscal Year)($1.37) Net Income$-72,160,000.00 Net Margins-383.19% Return on Equity-80.01% Return on Assets-60.20%Miscellaneous Employees119 Outstanding Shares54,264,000Market Cap$44.50 million Next Earnings Date8/1/2019 (Estimated) OptionableOptionable Tetraphase Pharmaceuticals (NASDAQ:TTPH) Frequently Asked Questions What is Tetraphase Pharmaceuticals' stock symbol? Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH." How were Tetraphase Pharmaceuticals' earnings last quarter? Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) issued its quarterly earnings data on Wednesday, May, 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.39) by $0.03. The biopharmaceutical company had revenue of $1.27 million for the quarter, compared to analysts' expectations of $1.93 million. Tetraphase Pharmaceuticals had a negative net margin of 383.19% and a negative return on equity of 80.01%. View Tetraphase Pharmaceuticals' Earnings History. When is Tetraphase Pharmaceuticals' next earnings date? Tetraphase Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Tetraphase Pharmaceuticals. What price target have analysts set for TTPH? 8 Wall Street analysts have issued 12 month target prices for Tetraphase Pharmaceuticals' shares. Their forecasts range from $1.40 to $7.00. On average, they anticipate Tetraphase Pharmaceuticals' share price to reach $4.20 in the next year. This suggests a possible upside of 412.2% from the stock's current price. View Analyst Price Targets for Tetraphase Pharmaceuticals. What is the consensus analysts' recommendation for Tetraphase Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tetraphase Pharmaceuticals in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tetraphase Pharmaceuticals. What are Wall Street analysts saying about Tetraphase Pharmaceuticals stock? Here are some recent quotes from research analysts about Tetraphase Pharmaceuticals stock: 1. According to Zacks Investment Research, "Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. " (5/16/2019) 2. Needham & Company LLC analysts commented, "Tetraphase reported $0.3M in U.S. Xerava sales, below our $2.5M and consensus $2M ests. We remain concerned that the commercial opportunity for the drug may be modest. Tetraphase continues to evaluate next-generation IV Gram- negative antibiotic 1 bronchopulmonary disposition trial. We expect an update on development strategy later this yr. Acinetobacter is a potential target pathogen. Preclinical studies of tetracycline oncology derivative TP-2846 are ongoing. Mgmt plans to provide more clarity around strategy and development path once these studies are completed. Maintain HOLD. We believe the company is likely to continue to face challenges w/ Xerava launch. Nevertheless, we have a favorable view toward decision to leverage synthetic tetracycline platform to expand into oncology." (5/12/2019) 3. HC Wainwright analysts commented, "We are highlighting three poster abstracts that are featured at MAD-ID as encore" presentations (and available on Tetraphase’s website), while looking forward to the release of two remaining poster abstracts after the MAD-ID meeting." (5/6/2019) Has Tetraphase Pharmaceuticals been receiving favorable news coverage? News headlines about TTPH stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tetraphase Pharmaceuticals earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the company's share price in the near future. Who are some of Tetraphase Pharmaceuticals' key competitors? Some companies that are related to Tetraphase Pharmaceuticals include Evofem Biosciences (EVFM), BELLUS Health (BLUSF), Chimerix (CMRX), Ardelyx (ARDX), Intec Pharma (NTEC), Axovant Gene Therapies (AXGT), BioXcel Therapeutics (BTAI), Cue Biopharma (CUE), TAIWAN LIPOSOME/S (TLC), Menlo Therapeutics (MNLO), REDHILL BIOPHAR/S (RDHL), Newron Pharmaceuticals (NWPHF), Strongbridge Biopharma (SBBP), LifeVantage (LFVN) and Checkpoint Therapeutics (CKPT). What other stocks do shareholders of Tetraphase Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tetraphase Pharmaceuticals investors own include Aurinia Pharmaceuticals (AUPH), Alcoa (AA), General Electric (GE), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Bank of America (BAC), Melinta Therapeutics (MLNT), Rite Aid (RAD), Opko Health (OPK) and Progenics Pharmaceuticals (PGNX). Who are Tetraphase Pharmaceuticals' key executives? Tetraphase Pharmaceuticals' management team includes the folowing people: Mr. Guy MacDonald B.Sc., B.Sc, CEO, Pres & Director (Age 60)Mr. Christopher Watt, Principal Financial & Accounting Officer (Age 54)Dr. Jacques Dumas, Chief Scientific Officer (Age 53)Ms. Maria D. Stahl, Sr. VP & Gen. Counsel (Age 48)Mr. Larry G. Edwards, Chief Operating Officer (Age 47) Who are Tetraphase Pharmaceuticals' major shareholders? Tetraphase Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.89%), Renaissance Technologies LLC (4.10%), Dimensional Fund Advisors LP (3.49%), Northern Trust Corp (1.11%), Acadian Asset Management LLC (1.03%) and Oxford Asset Management LLP (1.00%). Company insiders that own Tetraphase Pharmaceuticals stock include Jacques Dumas and L Patrick Gage. View Institutional Ownership Trends for Tetraphase Pharmaceuticals. Which major investors are selling Tetraphase Pharmaceuticals stock? TTPH stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Renaissance Technologies LLC, Man Group plc, Parametric Portfolio Associates LLC, Northern Trust Corp, BlackRock Inc., Alambic Investment Management L.P. and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for Tetraphase Pharmaceuticals. Which major investors are buying Tetraphase Pharmaceuticals stock? TTPH stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Edmond DE Rothschild Holding S.A., Royce & Associates LP and State of Wisconsin Investment Board. View Insider Buying and Selling for Tetraphase Pharmaceuticals. How do I buy shares of Tetraphase Pharmaceuticals? Shares of TTPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Tetraphase Pharmaceuticals' stock price today? One share of TTPH stock can currently be purchased for approximately $0.82. How big of a company is Tetraphase Pharmaceuticals? Tetraphase Pharmaceuticals has a market capitalization of $44.50 million and generates $18.90 million in revenue each year. The biopharmaceutical company earns $-72,160,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Tetraphase Pharmaceuticals employs 119 workers across the globe. What is Tetraphase Pharmaceuticals' official website? The official website for Tetraphase Pharmaceuticals is http://www.tphase.com/. How can I contact Tetraphase Pharmaceuticals? Tetraphase Pharmaceuticals' mailing address is 480 ARSENAL STREET SUITE 110, WATERTOWN MA, 02472. The biopharmaceutical company can be reached via phone at 617-715-3600 or via email at [email protected] MarketBeat Community Rating for Tetraphase Pharmaceuticals (NASDAQ TTPH)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 328 (Vote Outperform)Underperform Votes: 305 (Vote Underperform)Total Votes: 633MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe TTPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Fundamental Analysis and Individual Investors Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.